NON-HODGKIN'S LYMPHOMA

This early-stage study is testing a new experimental drug called GNC-038 in adults whose non-Hodgkin's lymphoma has come back or hasn't responded to other treatments. The main goals are to find a safe dose and see if the drug can help control the cancer. The drug is a special ant…

This study is testing a new combination of drugs to help collect stem cells from patients with non-Hodgkin's lymphoma. The stem cells are needed for a transplant, which is a treatment to control the cancer. Researchers want to see if the new drug mix works better and is safer tha…

This study is testing a new immune-boosting drug called glofitamab, given alone or with another drug (obinutuzumab), for people with B-cell non-Hodgkin's lymphoma that has come back or hasn't responded to prior treatments. The main goals are to find a safe and effective dose and …

This study is testing a new way to treat certain lymphomas linked to the Epstein-Barr virus (EBV). Doctors take a patient's own white blood cells, train them in a lab to recognize and attack EBV-infected cancer cells, and then infuse them back into the patient. The main goals are…

This is the first study in people testing an experimental oral drug called ABBV-525 for several types of advanced B-cell blood cancers, including lymphoma and leukemia. The main goals are to find a safe dose, see how the body processes the drug, and check for early signs that it …

This early-stage trial is testing a new experimental drug called GNC-035 in adults with non-Hodgkin's lymphoma or other blood cancers that have returned or not responded to standard treatments. The main goals are to find a safe dose and see if the drug shows early signs of fighti…

This study is collecting information on patient outcomes after receiving a cord blood transplant using Memorial Sloan Kettering's optimized procedure. It aims to see how well this standard transplant approach works for adults with high-risk blood cancers like leukemia, lymphoma, …

This study is testing if adding a pill called acalabrutinib to standard chemotherapy can help more people with an aggressive type of blood cancer called diffuse large B-cell lymphoma (DLBCL). It is for adults who have not yet started any treatment for their lymphoma. Researchers …

This is the first human study of an experimental drug called ABBV-291 for adults with non-Hodgkin's lymphoma that has returned or not responded to at least two prior treatments. The main goals are to find a safe dose, see how the body processes the drug, and check for early signs…

This is a first-in-human safety study testing a new personalized cell therapy called CLIC-2201. It is for adults and children with B-cell blood cancers (like leukemia and lymphoma) that have returned or not responded to other treatments. The main goal is to find the safest and mo…

This program provides early access to the drug venetoclax for patients with certain blood cancers like leukemia and lymphoma before it is fully approved in their country. It is for patients who have no other suitable treatment options and do not qualify for ongoing clinical trial…

This trial aims to find the safest and most effective way to prevent serious infections in adults with blood cancers like myeloma, lymphoma, and leukemia. It will directly compare two common prevention strategies: immunoglobulin therapy and antibiotics. The goal is to see which a…

This study collects health information from patients receiving stem cell transplants for various blood cancers and immune disorders. Researchers will track 2,000 patients over time to gather data on survival rates and treatment complications. The goal is to build a comprehensive …

This international study aims to create a better tool to predict survival for people with advanced mycosis fungoides and Sézary syndrome, two rare types of skin lymphoma. Researchers will follow 2,000 patients to collect detailed information about their disease and treatments. Th…

This study is a large registry that collects information on how adult patients with acute lymphoblastic leukemia (ALL) and related blood cancers are diagnosed and treated in real-world clinics. It aims to track patient outcomes, survival, and quality of life over time to help res…